State of the art biological therapies in pancreatic cancer

被引：26

作者：

Di Marco, Mariacristina ^{[1
]}

Grassi, Elisa ^{[1
]}

Durante, Sandra ^{[1
]}

Vecchiarelli, Silvia ^{[1
]}

Palloni, Andrea ^{[1
]}

Macchini, Marina ^{[1
]}

Casadei, Riccardo ^{[2
,3
]}

Ricci, Claudio ^{[2
]}

Panzacchi, Riccardo

Santini, Donatella ^{[3
]}

Biasco, Guido ^{[1
]}

机构：

[1] Univ Bologna, St Orsola Malpighi Hosp, Dept Expt Diagnost & Specialty Med, Massarenti St 11, I-40138 Bologna, Italy

[2] Univ Bologna, St Orsola Malpighi Hosp, Dept Med & Surg Sci, I-40138 Bologna, Italy

[3] St Orsola Malpighi Hosp, Pathol Unit, I-40138 Bologna, Italy

来源：

WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY | 2016年 / 8卷 / 01期

关键词：

Pancreatic cancer; Molecular characterization; Targeted therapy; Epidermal growth factor receptor inhibitors; Embryonic pathway inhibitors; Antiangiogenic therapies; PHASE-III TRIAL; GROWTH-FACTOR RECEPTOR; MTOR INHIBITOR EVEROLIMUS; GEMCITABINE PLUS PLACEBO; DOUBLE-BLIND; METASTATIC ADENOCARCINOMA; COMPARING GEMCITABINE; 1ST-LINE TREATMENT; ONCOLOGY-GROUP; COMBINATION;

D O I：

10.4251/wjgo.v8.i1.55

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies with a five-year survival rate of approximately 5%. Several target agents have been tested in PDAC, but almost all have failed to demonstrate efficacy in late phase clinical trials, despite the better understanding of PDAC molecular biology generated by large cancer sequencing initiatives in the past decade. Eroltinib (a small-molecule tyrosine-kinase inhibitor of epidermal growth factor receptor) plus gemcitabine is the only schedule with a biological agent approved for advanced pancreatic cancer, but it has resulted in a very modest survival benefit in unselected patients. In our work, we report a summary of the main clinical trials (closed and ongoing) that refer to biological therapy evaluation in pancreatic cancer treatment.

引用

页码：55 / 66

页数：12

共 77 条

[31] FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [J].

Conroy, Thierry ;

Desseigne, Francoise ;

Ychou, Marc ;

Bouche, Olivier ;

Guimbaud, Rosine ;

Becouarn, Yves ;

Adenis, Antoine ;

Raoul, Jean-Luc ;

Gourgou-Bourgade, Sophie ;

de la Fouchardiere, Christelle ;

Bennouna, Jaafar ;

Bachet, Jean-Baptiste ;

Khemissa-Akouz, Faiza ;

Pere-Verge, Denis ;

Delbaldo, Catherine ;

Assenat, Eric ;

Chauffert, Bruno ;

Michel, Pierre ;

Montoto-Grillot, Christine ;

Ducreux, Michel .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1817-1825

[32] A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma [J].

De Jesus-Acosta, Ana ;

Laheru, Daniel ;

Maitra, Anirban ;

Arcaroli, John ;

Rudek, Michelle A. ;

Dasari, Arvind ;

Blatchford, Patrick J. ;

Quackenbush, Kevin ;

Messersmith, Wells .

INVESTIGATIONAL NEW DRUGS, 2014, 32 (04) :739-745

[33] Roles for KRAS in Pancreatic Tumor Development and Progression [J].

di Magliano, Marina Pasca ;

Logsdon, Craig D. .

GASTROENTEROLOGY, 2013, 144 (06) :1220-1229

[34] Hedgehog signaling: From the cuirass to the heart of pancreatic cancer [J].

Di Marco, Mariacristina ;

Macchini, Marina ;

Vecchiarelli, Silvia ;

Sina, Sokol ;

Biasco, Guido .

PANCREATOLOGY, 2012, 12 (04) :388-393

[35] Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review) [J].

Di Marco, Mariacristina ;

Di Cicilia, Roberto ;

Macchini, Marina ;

Nobili, Elisabetta ;

Vecchiarelli, Silvia ;

Brandi, Giovanni ;

Biasco, Guido .

ONCOLOGY REPORTS, 2010, 23 (05) :1183-1192

[36] Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: A phase II study of the Hellenic Cooperative Oncology Group with biomarker evaluation [J].

Fountzilas, George ;

Bobos, Mattheos ;

Kalogera-Fountzila, Anna ;

Xiros, Nikolaos ;

Murray, Samuel ;

Linardou, Helena ;

Karayannopoulou, Georgia ;

Koutras, Angelos K. ;

Bafaloukos, Dimitrios ;

Samantas, Epaminondas ;

Christodoulou, Christos ;

Economopoulos, Theofanis ;

Kalogeras, Konstantine T. ;

Kosmidis, Paris .

CANCER INVESTIGATION, 2008, 26 (08) :784-793

[37] A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial [J].

Fuchs, C. S. ;

Azevedo, S. ;

Okusaka, T. ;

Van Laethem, J. -L. ;

Lipton, L. R. ;

Riess, H. ;

Szczylik, C. ;

Moore, M. J. ;

Peeters, M. ;

Bodoky, G. ;

Ikeda, M. ;

Melichar, B. ;

Nemecek, R. ;

Ohkawa, S. ;

Swieboda-Sadlej, A. ;

Tjulandin, S. A. ;

Van Cutsem, E. ;

Loberg, R. ;

Haddad, V. ;

Gansert, J. L. ;

Bach, B. A. ;

Carrato, A. .

ANNALS OF ONCOLOGY, 2015, 26 (05) :921-927

[38] Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer [J].

Harder, J. ;

Ihorst, G. ;

Heinemann, V. ;

Hofheinz, R. ;

Moehler, M. ;

Buechler, P. ;

Kloeppel, G. ;

Roecken, C. ;

Bitzer, M. ;

Boeck, S. ;

Endlicher, E. ;

Reinacher-Schick, A. ;

Schmoor, C. ;

Geissler, M. .

BRITISH JOURNAL OF CANCER, 2012, 106 (06) :1033-1038

[39] Tumour-stroma interactions in pancreatic ductal adenocarcinoma: Rationale and current evidence for new therapeutic strategies [J].

Heinemann, V. ;

Reni, M. ;

Ychou, M. ;

Richel, D. J. ;

Macarulla, T. ;

Ducreux, M. .

CANCER TREATMENT REVIEWS, 2014, 40 (01) :118-128

[40] Genetics and biology of pancreatic ductal adenocarcinoma [J].

Hezel, Aram F. ;

Kimmelman, Alec C. ;

Stanger, Ben Z. ;

Bardeesy, Nabeel ;

DePinho, Ronald A. .

GENES & DEVELOPMENT, 2006, 20 (10) :1218-1249

← 1 2 3 4 5 6 7 8 →